BioMarin Announces Selection of NAGLU Fusion Protein Drug Development Candidate BMN 250 for the Treatment of Sanfilippo B (MPS IIIB)
[GlobeNewswire] – Potential to Add Fourth MPS Treatment to BioMarin Franchise more
View todays social media effects on BMRN
View the latest stocks trending across Twitter. Click to view dashboard